Risk adjusted net present value: What is the current valuation of Forte Biosciences’s FB-102?

FB-102 is a monoclonal antibody commercialized by Forte Biosciences, with a leading Phase I program in Celiac Disease.

Mayo Clinic partners with supercomputing startup Cerebras to build custom AI tools

SAN FRANCISCO — Mayo Clinic has signed Silicon Valley tech startup Cerebras as its first generative AI partner, the health system announced Monday. The health

January 9, 2024

The past, present, and future of insects for human consumption

Researchers review data using insects as a sustainable and environmentally friendly source of protein, vitamins, and minerals.

August 11, 2023

Rescue from above: How drones may narrow emergency response times

The drones are coming. Starting in September, if someone in Clemmons, North Carolina, calls 911 to report a cardiac arrest, the first responder on the

July 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.